Buscar en
Revista Colombiana de Psiquiatría
Toda la web
Inicio Revista Colombiana de Psiquiatría Cuestionamientos y requerimientos en la investigación de la calidad de vida en ...
Journal Information
Vol. 39. Issue 1.
Pages 153-167 (March 2010)
Share
Share
Download PDF
More article options
Vol. 39. Issue 1.
Pages 153-167 (March 2010)
Artículos de revisión/actualización
Full text access
Cuestionamientos y requerimientos en la investigación de la calidad de vida en oncología
Questions and Requirements of Quality of Life Research in Oncology
Visits
1051
Carlos Eduardo Pinzón Flórez1,
Corresponding author
cepinzon@gmail.com

Correspondencia: Carlos Eduardo Pinzón Flórez, Maestría de Epidemiología Clínica y Bioestadística, Unidad de Epidemiología Clínica y Bioestadística, Pontificia Universidad Javeriana, Carrera 7 No. 40-62, Bogotá, Colombia
1 Médico. Estudiante de la Maestría de Epidemiología Clínica de la Pontificia Universidad Javeriana. Investigador del Instituto Nacional de Cancerología, Bogotá, Colombia
This item has received
Article information
Resumen
Introducción

Durante las dos últimas décadas ha habido una explosión de estudios de evaluación de la calidad de vida. En este estudio se abordaron las principales estrategias metodológicas, entre ellas la elección del instrumento óptimo, propiedades psicométricas básicas y tiempos de evaluación de la calidad de vida.

Objetivos

Proporcionar definiciones fundamentales útiles, describir las herramientas existentes y enunciar los desafíos en la interpretación de estudios de calidad de vida.

Método

Se realizó una búsqueda narrativa de la literatura con la siguiente estrategia de búsqueda: “(‘Quality of Life’[MeSH] AND (‘Research’[MeSH] OR ‘Epidemiologic Research Design’[MeSH] OR ‘Health Services Research’[MeSH])) AND (‘Oncology Service, Hospital’[MeSH] OR ‘Medical Oncology’[MeSH])”. La indagación contempló el período comprendido entre 1966 y 2007. La estrategia de búsqueda fue adaptada a cada una de las bases de datos consultadas: Medline, Cochrane, LILACS y SciELO.

Resultados

Se encontraron, por título y resumen, 189 artículos, a criterio de los autores, de los cuales fueron seleccionados 54 para esta revisión. No se obtuvieron cuatro artículos, por no tener acceso a los correspondientes journals.

Conclusiones

La calidad de vida se ha convertido en un tema de interés para muchos investigadores en oncología, ya que no es suficiente con aumentar el tiempo de sobrevida, sino garantizar un estándar de calidad de vida generado a partir del tratamiento médico.

Palabras clave:
calidad de vida
cáncer
estudios de validación
oncología médica
Abstract
Introduction

During the last two decades, there has been an explosion of studies assessing the quality of life. Main methodological strategies have been addressed, including the optimal choice of instrument, basic psychometric properties and times of evaluation of quality of life.

Objectives

To provide basic definitions and tools, to describe the existing tools, and to articulate the challenges of interpreting studies of quality of life.

Methods

We conducted a narrative literature search with the following search strategy “(‘Quality of Life’[MeSH] AND (‘Research’[MeSH] OR ‘Epidemiologic Research Design’[MeSH] OR ‘Health Services Research’[MeSH])) AND (‘Oncology Service, Hospital’[MeSH] OR ‘Medical Oncology’ [MeSH]). The search comprised the period between 1966 and 2007. The search strategy was adapted to each of the searchable databases: Medline, Cochrane, LILACS and SciELO.

Results

189 articles were found by title and abstract, of which 54 were selected for this review. Four articles were not obtained for not having access to relevant journals.

Conclusions

The quality of life has become a topic of interest to many researchers in oncology since it is not enough to increase survival time, inasmuch as a standard quality of life must ensue from the medical treatment as well.

Key words:
Quality of life
neoplasms
validation studies
medical oncology
Full text is only aviable in PDF
Referencias
[1]
P Fayers, D Machin.
Quality of life assessment, analysis and interpretation, John Wiley & Sons, (2000),
[2]
ME Hyland.
Health and values: the values underlying health measurement and health resource.
Psych Health, 12 (1997), pp. 389-403
[3]
A Leplège, S Hunt.
The problem of quality of life in medicine.
JAMA, 278 (1997), pp. 47-50
[4]
J Till, B McNeil, R Bush.
Measurements of multiple components of quality of life.
Cancer Treat Symp, 1 (1984), pp. 177-181
[5]
ML Slevin, H Plant, D Lynch, J Drinkwater, WM Gregory.
Who should measure quality of life, the doctor or the patient?.
Br J Cancer, 57 (1988), pp. 109-112
[6]
E Beller, M Tattersall, T Lumley, J Levi, D Dalley, I Olver, et al.
Improved quality of life with megestrol acetate in patients with endocrine-insensitive advanced cancer: A randomised placebo controlled trial.
Ann Oncol, 8 (1997), pp. 277-283
[7]
A Coates, V Gebski, J Bishop, et al.
Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies.
N Engl J Med, 317 (1987), pp. 1490-1495
[8]
A Coates.
Prognostic implications of quality of life.
Cancer Treat Rev, 19 Suppl A (1993), pp. 53-57
[9]
A Montazeri, R Milroy, D Hole, J McEwen, CR Gillis.
Quality of life in lung cancer patients: as an important prognostic factor.
Lung Cancer, 31 (2001), pp. 233-240
[10]
A Bottomley, NK Aaronson, European Organization for Research and Treatment of Cancer.
International perspective on health-related quality-of-life research in cancer clinical trials: the European Organization for Research and Treatment of Cancer experience.
J Clin Oncol, 25 (2007), pp. 5082-5086
[11]
H Langendijk, NK Aaronson, JM de Jong, GP ten Velde, MJ Muller, M Wouters.
The prognostic impact of quality of life assessed with the EORTC QLQ-C30 in inoperable non-small cell lung carcinoma treated with radiotherapy.
Radiother Oncol, 55 (2000), pp. 19-25
[12]
EM Smets, MR Visser, AF Willems-Groot, B Garssen, AL Schuster-Uitterhoeve, JC de Haes.
Fatigue and radiotherapy: (B) Experience in patients 9 months following treatment.
Br J Cancer, 78 (1998), pp. 907-912
[13]
H Burris 3rd, MJ Moore, J Andersen, MR Green, ML Rothenberg, MR Modiano, et al.
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
J Clin Oncol, 15 (1997), pp. 2403-2413
[14]
K Bjordal, S Kaasa, A Mastekaasa.
Quality of life in patients treated for head and neck cancer: A follow-up study 7 to 11 years after radiotherapy.
Int J Radiat Oncol Biol Phys, 28 (1994), pp. 847-856
[15]
K Bjordal, S Kaasa.
Psychological distress in head and neck cancer patients 7-11 years after curative treatment.
Br J Cancer, 71 (1995), pp. 592-597
[16]
B Movsas.
Exploring the role of the radioprotector amifostine in locally advanced non-small cell lung cancer: Radiation Therapy Oncology Group trial 98-01.
Semin Radiat Oncol, 12 (2002), pp. 40-45
[17]
C Leitgeb, M Pecherstorfer, E Fritz, H Ludwig.
Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin.
Cancer, 73 (1994), pp. 2535-2542
[18]
D Revicki, D Osoba, D Fairclough, I Barofsky, R Berzon, NK Leidy, et al.
Recommendations on health-related quality of life research to support labeling and promotional claims in the United States.
Qual Life Res, 9 (2000), pp. 887-900
[19]
NK Leidy, DA Revicki, B Genesté.
Recommendations for evaluating the validity of quality of life claims for labeling and promotion.
Value Health, 2 (1999), pp. 113-127
[20]
O Chassany, P Sagnier, P Marquis, S Fullerton, N Aaronson.
Patient-reported outcomes: the example of health-related quality of life: A European guidance document for the improved integration of health-related quality of life assessment in the drug regulatory process.
Drug Inf J, 36 (2002), pp. 209-238
[21]
CC Gotay, M Wilson.
Use of quality-of-life outcome assessments in current cancer clinical trials.
Eval Health Prof, 21 (1998), pp. 157-178
[22]
J Johnson, R Temple.
Food and Drug Administration requirements for approval of new anti-cancer drugs.
Cancer Treat Rep, 69 (1985), pp. 1155-1157
[23]
SB Detmar, NK Aaronson, LD Wever, M Muller, JH Schornagel.
How are you feeling? Who wants to know? Patients’ and oncologists’ preferences for discussing health-related quality-of-life issues.
J Clin Oncol, 18 (2000), pp. 3295-3301
[24]
M Slevin, L Stubbs, HJ Plant, P Wilson, WM Gregory, PJ Armes, et al.
Attitudes to chemotherapy: Comparing views of patients with cancer with those of doctors, nurses, and general public.
BMJ, 300 (1990), pp. 1458-1460
[25]
J Strain.
The evolution of quality-of-life evaluations in cancer therapy.
Oncology, 4 (1990), pp. 22-26
[26]
DF Cella, DS Tulsky.
Measuring quality of life today: methodological aspects.
Oncology (Williston Park), 4 (1990), pp. 29-38
[27]
A Bezjak, KM Taylor, P Ng, K Macdonald, AD DePetrillo.
Quality-of-life information and clinical practice: the oncologist's perspective.
Cancer Prev Control, 2 (1998), pp. 230-235
[28]
SJ Coons, S Rao, DL Keininger, RD Hays.
A comparative review of generic quality-of-life instruments.
Pharmacoeconomics, 17 (2000), pp. 13-35
[29]
N Laliberte, D Cella, G Masters.
Realtime clinical application of quality of life (QOL) assessment in lung cancer: a feasibility pilot.
Qual Life Res, 9 (2000), pp. 293-295
[30]
M Brundage, D Osoba, A Bezjak, D Tu, M Palmer, J Pater, National Cancer Institute of Canada Clinical Trials Group.
Lessons learned in the assessment of health-related quality of life: selected examples from the National Cancer Institute of Canada Clinical Trials Group.
J Clin Oncol, 25 (2007), pp. 5078-5081
[31]
D Osoba.
The Quality of Life Committee of the Clinical Trials Group of the National Cancer Institute of Canada: organization and functions.
Qual Life Res, 1 (1992), pp. 211-218
[32]
R Gelber, S Gelber.
Quality of life assessment in clinical trials: recent advances in clinical trial design and analysis, Kluwer Academic, (1995),
[33]
D Osoba, A Bezjak, M Brundage, J Pater, National Cancer Institute of Canada Clinical Trials Group.
Evaluating health-related quality of life in cancer clinical trials: the National Cancer Institute of Canada Clinical Trials Group experience.
Value Health, 10 (2007), pp. S138-S145
[34]
N Aaronson.
Quality of Life and clinical trials.
Lancet, 346 (1995), pp. 1-2
[35]
CC Gotay, TD Moore.
Assessing quality of life in head and neck cancer.
Qual Life Res, 1 (1992), pp. 5-17
[36]
SD Passik, KL Kirsh.
The importance of quality-of-life endpoints in clinical trials to the practicing oncologist.
Hematol Oncol Clin North Am, 14 (2000), pp. 877-886
[37]
JE Ware Jr.
Standards for validating health measures: definition and content.
J Chronic Dis, 40 (1987), pp. 473-480
[38]
JA Husted, RJ Cook, VT Farewell, DD Gladman.
Methods for assessing responsiveness: A critical review and recommendations.
J Clin Epidemiol, 53 (2000), pp. 459-468
[39]
F Roila, E Cortesi.
Quality of life as a primary end point in oncology.
Ann Oncol, 12 Suppl 3 (2001), pp. S3-S6
[40]
J Von Neumann, O Morgenstern.
Theory of games and economic behavior, Princeton University, (1944),
[41]
The Netherlands Cancer Institute, Amsterdam.
Assessing health status and quality-of-life instruments: attributes and review criteria.
Qual Life Res, 11 (2002), pp. 193-205
[42]
C Joyce, C O'Boyle, H McGee.
Individual quality of life: approaches to conceptualisation and assessment, Harwood Academic, (1999),
[43]
MA Testa, DC Simonson.
Assesment of quality-of-life outcomes.
N Engl J Med, 334 (1996), pp. 835-840
[44]
NK Aaronson, S Ahmedzai, B Bergman, M Bullinger, A Cull, NJ Duez, et al.
The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.
J Natl Cancer Inst, 85 (1993), pp. 365-376
[45]
DF Cella, DS Tulsky, G Gray, B Sarafian, E Linn, A Bonomi, et al.
The functional assessment of Cancer Therapy Scale: development and validation of the general measure.
J Clin Oncol, 11 (1993), pp. 570-579
[46]
Fayers P, Weeden S, Curran D. EORTC QLQ-C30 reference values. Brussels: 1998.
[47]
MJ Hjermstad, PM Fayers, K Bjordal, S Kaasa.
Health-related quality of life in the general Norwegian population assessed by the EORTC core Quality of Life Questionnaire The QLQ=C30 (+ 3).
J Clin Oncol, 16 (1998), pp. 1188-1196
[48]
JC de Haes, FC van Knippenberg, J Neijt.
Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam Symptom Checklist.
Br J Cancer, 62 (1990), pp. 1034-1038
[49]
R McCorkle, K Young.
Development of a symptom distress scale.
Cancer Nurs, 1 (1978), pp. 373-378
[50]
H Schipper, J Clinch, A McMurray, M Levitt.
Measuring the quality of life of cancer patients: the Functional Living Index-Cancer: development and validation.
J Clin Oncol, 2 (1984), pp. 472-483

Conflicto de interés: el autor manifiesta que no tiene ningún conflicto de interés en este artículo.

Copyright © 2010. Asociación Colombiana de Psiquiatría
Article options
Tools